2 terminated, 1 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Recruiting 1 |
Follow Frontotemporal Dementia, Behavioral Variant: new trials by email Literature Review of Frontotemporal Dementia, Behavioral Variant trials Research Report on Frontotemporal Dementia, Behavioral Variant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia Vortioxetine - Fronto-temporal Dementia, Fronto-temporal Lobar Dementia | Phase 2 | Recruiting | Johns Hopkins University | 50 | 2025-03-20 | 2026-03-09 |
| Nabilone for Agitation in Frontotemporal Dementia Nabilone, Placebo - Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant | Phase 2 | Terminated | Simon Ducharme, MD | 3 | 2023-03-07 | 2026-07-28 |
| Intranasal Insulin in Frontotemporal Dementia (FTD) Novolin-R insulin - Frontotemporal Dementia, Behavioral Variant | Phase 2 | Terminated | HealthPartners Institute | 3 | 2019-09-09 | 2023-10-27 |
Pick Disease of the Brain (3) · Frontotemporal Dementia (2) · Aphasia, Primary Progressive (1) · Dementia (1) · Insulin Resistance (1) · Psychomotor Agitation (1)
Brain Diseases (3) · Central Nervous System Diseases (3) · Frontotemporal Lobar Degeneration (3) · Mental Disorders (3) · Metabolic Diseases (3) · Nervous System Diseases (3) · Neurocognitive Disorders (3) · Nutritional and Metabolic Diseases (3) · Dementia (2) · Neurodegenerative Diseases (2) · Proteostasis Deficiencies (2) · TDP-43 Proteinopathies (2) · Aberrant Motor Behavior in Dementia (1) · Aphasia (1) · Behavior (1)
Insulin (1) · Vortioxetine (1) · nabilone (1)
HealthPartners Institute (1) · Johns Hopkins University (1) · Simon Ducharme, MD (1)
United States (2) · Canada (1)
Christopher Morrow, MD (1) · Michael H Rosenbloom, MD (1)
K23AG088248 (1)